688276.SH
百克生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 16.22
−6.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 590.1M | 605.1M | 1.2B | 1.8B | 1.1B |
| Cost of Revenue | 164.9M | 160.7M | 179.2M | 178.2M | 137.2M |
| Gross Profit | 425.2M | 444.3M | 1.0B | 1.6B | 934.2M |
| Operating Expenses | |||||
| R&D Expense | 172.6M | 177.1M | 156.1M | 198.1M | 133.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 101.9M | 110.7M | 112.9M | 159.3M | 144.5M |
| Selling & Marketing Expense | 380.7M | 389.3M | 475.0M | 647.2M | 411.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 665.2M | 686.1M | 750.2M | 1.0B | 679.2M |
| Cost and Expenses | 830.1M | 846.8M | 929.4M | 1.2B | 816.4M |
| Operating Income (EBIT) | (331.5M) | (332.3M) | 257.9M | 559.3M | 186.9M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (336.0M) | (331.9M) | 255.8M | 563.8M | 197.7M |
| Income Tax Expense | (68.9M) | (69.3M) | 23.7M | 62.7M | 16.2M |
| Bottom Line | |||||
| Net Income | (267.1M) | (262.6M) | 232.1M | 501.0M | 181.5M |
| Earnings from Cont. Ops | (267.1M) | (262.6M) | 232.1M | 501.0M | 181.5M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (267.1M) | (262.6M) | 232.1M | 501.0M | 181.5M |
| Per Share | |||||
| Basic EPS | (CN¥0.65) | (CN¥0.64) | CN¥0.56 | CN¥1.21 | CN¥0.44 |
| Diluted EPS | (CN¥0.65) | (CN¥0.64) | CN¥0.56 | CN¥1.21 | CN¥0.44 |
| Revenue Per Share | CN¥1.70 | CN¥1.47 | CN¥2.97 | CN¥4.41 | CN¥2.60 |
| Shares | |||||
| Basic Shares Outstanding | 347.4M | 410.3M | 414.5M | 414.1M | 412.6M |
| Diluted Shares Outstanding | 347.4M | 410.3M | 414.5M | 414.1M | 412.6M |
| Profitability Metrics | |||||
| EBITDA | — | (182.2M) | 371.2M | 658.3M | 263.5M |
| D&A | — | 150.1M | 113.3M | 99.0M | 76.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026